AbbVie

Wooden blocks with arrow and error icon Delays and disruptions stop the process critical error concept
Biotech

FDA rejects Aldeyra eye disease candidate for 3rd time

AbbVie has an option agreement for reproxalap, making Aldeyra eligible for a $100 million payment if the FDA approves the drug in dry eye disease.
Gabrielle Masson Mar 17, 2026 11:12am
obesity overweight weight loss weigh

AbbVie ties $350M bet to almost 10% weight loss after 12 weeks

Mar 9, 2026 9:50am
two baskets of eggs on a farm

Boehringer axes MASH deal after OSE asset fails to show efficacy

Mar 2, 2026 2:16pm
Glowing puzzle piece fitting into puzzle

AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF race

Jan 12, 2026 11:00am
holiday Christmas presents shopping cart

AbbVie, Gilead gift themselves clinical-stage cancer drugs

Jan 2, 2026 10:35am
Abstract modern white spiral clock dial with roman and arabic numerals

Aldeyra dry eye disease decision hit by FDA delay

Dec 16, 2025 11:55am